Inflammatory bowel disease and lupus: A systematic review of the literature

Journal of Crohn's and Colitis

Volumn 6, Issue 7, 2012, Pages 735-742

  Katsanos, Konstantinos H ^a   Voulgari, Paraskevi V ^a   Tsianos, Epameinondas V ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Crohn's disease; Inflammatory bowel disease; Lupus; Systemic lupus erythematosus; Ulcerative colitis; Vasculitis

Indexed keywords

ADALIMUMAB; AUTOANTIBODY; CERTOLIZUMAB PEGOL; CYCLOPHOSPHAMIDE; DNA ANTIBODY; INFLIXIMAB; MESALAZINE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

ALGORITHM; ANTIBODY PRODUCTION; COMORBIDITY; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; ENTERITIS; HUMAN; LUPUS ERYTHEMATOSUS; LUPUS ERYTHEMATOSUS NEPHRITIS; LUPUS LIKE SYNDROME; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYMPTOM; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MESALAMINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84863498760     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2012.03.005     Document Type: Review

References (78)

1. Lee C.K., Lee T.H., Lee S.H., Chung I.K., Park S.H., Kim H.S., et al. GI vasculitis associated with systemic lupus erythematosus. Gastrointest Endosc 2010, 72:618-619.
2. Tian X.P., Zhang X. Gastrointestinal involvement in systemic lupus erythematosus: insight into pathogenesis, diagnosis and treatment. World J Gastroenterol 2010, 28(16):2971-2977.
3. Ebert E.C., Hagspiel K.D. Gastrointestinal and hepatic manifestations of systemic lupus erythematosus. J Clin Gastroenterol 2011, 45:436-441.
4. Sultan S.M., Ioannou Y., Isenberg D.A. A review of gastrointestinal manifestations of systemic lupus erythematosus. Rheumatology 1999, 38:917-932.
5. Gladman D.D., Ross T., Richardson B., Kulkarni S. Bowel involvement in systemic lupus erythematosus: Crohn's disease or lupus vasculitis?. Arthritis Rheum 1985, 28:466-470.
6. Daruwala C., Mercogliano G., Harder T.P. Gastrointestinal manifestations of systemic lupus erythematosus and scleroderma. Clin Med Gastroenterol 2009, 2:7-12.
7. Luman W., Chua K.B., Cheong W.K., Ns H.S. Gastrointestinal manifestations of systemic lupus eryhtematosus. Singapore Med J 2001, 42:380-384.
8. Tsuchiya M., Okazaki I., Asakura H., Okubo T. Radiographic and endoscopic features of colonic ulcers in systemic lupus erythematosus. Am J Gastroenterol 1975, 64:277-285.
9. Grimbacher B., Huber M., von Kempis J., Kalden P., Uhl M., Köhler G., et al. Successful treatment of gastrointestinal vasculitis due to systemic lupus erythematosus with intravenous pulse cyclophosphamide: a clinical case report and review of the literature. Br J Rheumatol 1998, 37:1023-1028.
10. Ferreiros-Vidal I., Garcia-Meijide J., Carreira P., Barros F., Carracedo A., Gomez-Reino J.J., et al. The three most common CARD15 mutations associated with Crohn's disease and the chromosome 16 susceptibility locus for systemic lupus erythematosus. Rheumatology (Oxford) 2003, 42:570-574.
11. De Jager P.L., Graham R., Farwell L., Sawcer S., Richardson A., Behrens T.W., et al. The role of inflammatory bowel disease susceptibility loci in multiple sclerosis and systemic lupus erythematosus. Genes Immun 2006, 7:327-334.
12. Fujimori J., Yoshino S., Morishige T., Kishimoto M., Suzuki N., Ohba H. A case of rheumatoid arthritis with systemic lupus erythematosus, Sjögren's syndrome and Crohn's disease. Ryumachi 1987, 27:294-300.
13. Su K.Y., Tsai S.T., Tsay S.H., Lee H.T., Chen W.S., Huang D.F. A patient with systemic lupus erythematosus and Crohn's disease complicated with massive lower gastrointestinal bleeding, mimicking intestinal vasculitis. Lupus 2008, 17:1049-1050.
14. Johnson D.A., Diehl A.M., Finkelman F.D., Cattau E.L. Crohn's disease and systemic lupus erythematosus. Am J Gastroenterol 1985, 80:869-870.
15. Sanchez-Burson J., Garcia-Porrua C., Melguizo M.I., Gonzalez-Gay M.A. Systemic lupus erythematosus and Crohn's disease: an uncommon association of two autoimmune diseases. Clin Exp Rheumatol 2004, 22:133.
16. Toulemonde P., Alric L., Vallée F., Selves J., Duffaut M. Association of disseminated lupus erythematosus and Crohn's disease. Rev Med Interne 2001, 22:385-388.
17. Mornet P., Lafon J., de Mouilliac M.V., Morin M. Lupus associated with ileocolitis following tuberculostatic treatment (lupus and Crohn's disease). Sem Hop 1973, 26(49):2199-2207.
18. Principi M., Di Leo A., Ingrosso M., Pisani A., Marangi S., Amoruso A., et al. Lupus nephritis improvement after anti-tumor necrosis factor alpha monoclonal antibody (infliximab) treatment for Crohn's disease: a case report. Immunopharmacol Immunotoxicol 2004, 26:243-248.
19. Sugimoto M., Sato Y., Kumagai Y., Suenaga M., Hashimoto H., Hirose S. A case of systemic lupus erythematosus with lupus nephritis occurring in Crohn's disease. Nippon Naika Gakkai Zasshi 1989, 78:583-584.
20. Nishida Y., Murase K., Ashida R., Sasaki O., Ozono Y., Mizuta Y., et al. Familial Crohn's disease with systemic lupus erythematosus. Am J Gastroenterol 1998, 93:2599-2601.
21. Ashworth J. Subacute cutaneous lupus erythematosus in a patient with Crohn's disease. Clin Exp Dermatol 1992, 17:135-136.
22. Shafer R.B., Gregory D.H. Systemic lupus erythematosus presenting as regional ileitis. Minn Med 1970, 53:789-792.
23. Dubrow M.H., McPherson J.R., Bowie J.W. Lupus erythematosus presenting as an acute abdomen. Minn Med 1966, 49:577-579.
24. Shimizu T., Nishinarita S., Son K., Tomita Y., Yoshihiro, Matsukawa T., et al. Crohn's disease with the onset resembling systemic lupus erythematosus. Nihon Rinsho Meneki Gakkai Kaishi 1999, 22:164-169.
25. Buchman A.L., Wilcox C.M. Crohn's disease masquerading as systemic lupus erythematosus. South Med J 1995, 88:1081-1083.
26. Hayden G.M., Atlas S.A. Strongyloidiasis masquerading as inflammatory bowel disease in a patient with lupus erythematosis: a case report. St. Joseph Hospital, Stamford, USA. Conn Med 1995, 59:649-650.
27. Chamouard P., Grunebaum L., Wiesel M.L., Freyssinet J.M., Duclos B., Cazenave J.P., et al. Prevalence and significance of anticardiolipin antibodies in Crohn's disease. Dig Dis Sci 1994, 39:1501-1504.
28. Mevorach D., Goldberg Y., Gomori J.M., Rachmilewitz D. Antiphospholipid syndrome manifested by ischemic stroke in a patient with Crohn's disease. J Clin Gastroenterol 1996, 22:141-143.
29. Vianna J.L., D'Cruz D.P., Khamashta M.A., Asherson R.A., Hughes G.R. Anticardiolipin antibodies in a patient with Crohn's disease and thrombosis. Clin Exp Rheumatol 1992, 10:165-168.
30. Brown C.H., Haserick J.R., Shirey E.K. Chronic ulcerative colitis with systemic lupus erythematosus. Report of a case. Cleve Clin Q 1956, 23:43-46.
31. Dubois E.L., Tuffanelli D.L. Clinical manifestatiosn of systemic lupus erythematosus. JAMA 1964, 190:104-111.
32. Font J., Bosch X., Ferrer J., Pérez-Villa F., Ingelmo M. Systemic lupus erythematosus and ulcerative colitis. Lancet 1988, 1:770.
33. Medeiros D.A., Isenberg D.A. Systemic lupus erythematosus and ulcerative colitis. Lupus 2009, 18:762-763.
34. Bourikas L.A., Tzardi M., Hatzidakis A., Koutroubakis I.E. Small bowel perforation due to non-Hodgkin-lymphoma in a patient with ulcerative colitis and systemic lupus erythematosus. Dig Liver Dis 2008, 40:144.
35. Nieradko-Iwanicka B., Majdan M., Piotrowski M., Radwan P., Kwiatkowski P. Association of ulcerative colitis and lupus nephropathy-report of two cases. Pol Arch Med Wewn 2006, 115:559-564.
36. Sugiyama T., Oishi Y., Sueishi M., Matsumura R., Tomioka H., Akikusa B. Diffuse proliferative lupus nephritis in a patient with ulcerative colitis. Ryumachi 1996, 36:651-655.
37. Garcia-Porrua C., Gonzalez-Gay M.A., Lancho A., Alvarez-Ferreira J. Systemic lupus erythematosus and ulcerative colitis: an uncommon association. Clin Exp Rheumatol 1998, 16:511.
38. Koutroubakis I.E., Kritikos H., Mouzas I.A., Spanoudakis S.M., Kapsoritakis A.N., Petinaki E., et al. Association between ulcerative colitis and systemic lupus erythematosus: report of two cases. Eur J Gastroenterol Hepatol 1998, 10:437-439.
39. Ishikawa O., Miyachi Y., Fujita K., Takenoshita S., Nagamachi Y., Hirato J. Ulcerative colitis associated with preceding systemic lupus erythematosus. J Dermatol 1995, 22:289-291.
40. Stevens H.P., Ostlere L.S., Rustin M.H. Systemic lupus erythematosus in association with ulcerative colitis: related autoimmune diseases. Br J Dermatol 1994, 130:385-389.
41. Papi C., Ciaco A., Acierno G., Di Battista G., Talamanca L.F., Lo Russo F., et al. Severe ulcerative colitis, dural sinus thrombosis, and the lupus anticoagulant. Am J Gastroenterol 1995, 90:1514-1517.
42. Jaup B.H. Salazosulfapyridine-induced lupus erythematosus syndrome in ulcerative colitis (author's transl). Dtsch Med Wochenschr 1978, 103:1211-1213.
43. Gunnarsson I., Pettersson E., Lindblad S., Ringertz B. Olsalazine-induced lupus syndrome. Scand J Rheumatol 1997, 26:65-66.
44. Clementz G.L., Dolin B.J. Sulfasalazine-induced lupus erythematosus. Am J Med 1988, 84:535-538.
45. Griffiths I.D., Kane S.P. Sulphasalazine-induced lupus syndrome in ulcerative colitis. Br Med J 1977, 2:1188-1189.
46. Vanheule B.A., Carswell F. Sulphasalazine-induced systemic lupus erythematosus in a child. Eur J Pediatr 1983, 140:66-68.
47. Carr-Locke D.L. Sulfasalazine-induced lupus syndrome in a patient with Crohn's disease. Am J Gastroenterol 1982, 77:614-616.
48. Gunnarsson I., Forslid J., Ringertz B. Mesalazine-induced lupus syndrome. Lupus 1999, 8:486-488.
49. Pent M.T., Ganapathy S., Holdsworth C.D., Channer K.C. Mesalazine induced lupus-like syndrome. BMJ 1992, 305:159.
50. Vermeire S., Noman M., Van Assche G., Baert F., Van Steen K., Esters N., et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 2003, 125:32-39.
51. Kirkpatrick A.W., Bookman A.A., Habal F. Lupus-like syndrome caused by 5-aminosalicylic acid in patients with inflammatory bowel disease. Can J Gastroenterol 1999, 13:159-162.
52. Timsit M.A., Anglicheau D., Lioté F., Marteau P., Dryll A. Mesalazine-induced lupus. Rev Rhum Engl Ed 1997, 64:586-588.
53. Gunnarsson I., Kanerud L., Pettersson E., Lundberg I., Lindblad S., Ringertz B. Predisposing factors in sulphasalazine-induced systemic lupus erythematosus. Br J Rheumatol 1997, 36:1089-1094.
54. Mageed R.A., Isenberg D.A. Tumour necrosis factor alpha in systemic lupus erythematosus and anti-DNA autoantibody production. Lupus 2002, 11:850-855.
55. Atzeni F., Ardizzone S., Sarzi-Puttini P., Colombo E., Maconi G., De Portu S., et al. Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study. Aliment Pharmacol Ther 2005, 22:453-461.
56. Nancey S., Blanvillain E., Parmentier B., Flourié B., Bayet C., Bienvenu J., et al. Infliximab treatment does not induce organ-specific or nonorgan-specific autoantibodies other than antinuclear and anti-double-stranded DNA autoantibodies in Crohn's disease. Inflamm Bowel Dis 2005, 11:986-991.
57. Clark M., Colombel J.F., Feagan B.C., Fedorak R.N., Hanauer S.B., Kamm M.A., et al. AGA consensus development conference on the use of biologics in the treatment of inflammatory bowel disease. Gastroenterology 2007, 133:312-339.
58. Schiff M.H., Burmester G.R., Kent J.D., Pangan A.L., Kupper H., Fitzpatrick S.B., et al. Safety analyses of adalimumab (Humira) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006, 65:889-894.
59. Klapman J.B., Ene-Stroescu D., Becker M.A., Hanauer S.B. A lupus-like syndrome associated with infliximab therapy. Inflamm Bowel Dis 2003, 9:176-178.
60. Garcia-Planella E., Domènech E., Esteve-Comas M., Bernal I., Cabré E., Boix J., et al. Development of antinuclear antibodies and its clinical impact in patients with Crohn's disease treated with chimeric monoclonal anti-TNFalpha antibodies (infliximab). Eur J Gastroenterol Hepatol 2003, 15:351-354.
61. Levine D., Switlyk S.A., Gottlieb A. Cutaneous lupus erythematosus and anti-TNF-alpha, therapy: a case report with review of the literature. J Drugs Dermatol 2010, 9:1283-1287.
62. Vermeire S., Rutgeerts P. Antibody responses in Crohn's disease. Gastroenterology 2004, 126:601-604.
63. Colombel J.F., Loftus E.V., Tremaine W.J., Egan L.J., Harmsen W.S., Schleck C.D., et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004, 126:19-31.
64. Sandborn WJ on behalf of the CLASSIC-II study authors Adalimumab-induced lupus erythematosus in Crohn's disease patients previously treated with infliximab. Gut 2008, 57:559-560.
65. Colombel J.F., Sandborn W.J., Panaccione R., Robinson A.M., Lau W., Li J., et al. Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm Bowel Dis 2009, 15:1308-1319.
66. Jeudy G., Dutronc Y., Galliot-Repkat C., Dupuis J., Jolimoy G., Lambert D., et al. Infliximab-induced skin reaction with visceral manifestations and high levels of anti-DNA antibodies. Ann Dermatol Venereol 2007, 134:268-271.
67. Sarzi-Puttini P., Ardizzone S., Manzionna G., Atzeni F., Colombo E., Antivalle M., et al. Infliximab-induced lupus in Crohn's disease: a case report. Dig Liver Dis 2003, 35:814.
68. Beuthien W., Mellinghoff H.U., von Kempis J. Skin reaction to adalimumab. Arthritis Rheum 2004 May, 50(5):1690-1692.
69. Sandborn W.J., Hanauer S.B., Rutgeerts P., Fedorak R.N., Lukas M., MacIntosh D.G., et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007, 56:1232-1239.
70. Martín J.M., Ricart J.M., Alcácer J., Rausell N., Arana G. Adalimumab-induced lupus erythematosus. Lupus 2008, 17:676-678.
71. Costa M.F., Said N.R., Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 2008, 37:381-387.
72. Colombel J.F. Efficacy and safety of adalimumab for the treatment of Crohn's disease in adults. Expert Rev Gastroenterol Hepatol 2008, 2:163-176.
73. Mañosa M., Domènech E., Marín L., et al. Adalimumab-induced lupus erythematosus in Crohn's disease patients previously treated with infliximab. Gut 2008, 57:559.
74. van Rijthoven A.W., van Roon J.A. Drug-induced systemic lupus erythematosus: reports to The Netherlands Pharmacovigilance Centre. Ned Tijdschr Geneeskd 2007, 151:839.
75. Kocharla L., Mongey A.B. Is the development of drug-related lupus a contraindication for switching from one TNF alpha inhibitor to another?. Lupus 2009, 18:169-171.
76. Subramanian S., Yajnik V., Sands B.E., Cullen G., Korzenik J.R. Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent. Inflamm Bowel Dis 2011, 17:99-104.
77. Beigel F., Schnitzler F., Paul Laubender R., Pfennig S., Weidinger M., Göke B., et al. Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-α antibody-treated patients with inflammatory bowel disease. Inflamm Bowel Dis 2011, 17:91-98.
78. Youdim A., Vasiliauskas E.A., Targan S.R., Papadakis K.A., Ippoliti A., Dubinsky M.C., et al. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis 2004, 10:333-338.